BTIG lowered the firm’s price target on Precision BioSciences to $2 from $6 and keeps a Buy rating on the shares. The firm adjusts its model to push out its assumed U.S. market launch of Azer-cel to 2027 and EU launch to 2028, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue